The company remains in a pre-revenue phase with persistent operating losses that fluctuated between $1.3M and $3.9M per quarter, exacerbated by R&D expenditures that peaked at $1.6M in 2025Q1.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 922.41K | 0 | 0 | 0 | 5.97K | 60.83K | 54.95K | 18K | 18.74K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -922.41K | 0 | 0 | 0 | -5.97K | -60.83K | -54.95K | -18K | -18.74K |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | 100% | 90.18% | -10.71% | -205.28% | 3.94% | - |
| Operating Expenses | 10.26M | 11.92M | 7.7M | 5.89M | 2.34M | 1.68M | 454.57K | 568.63K | 185.15K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 7.65M | 7.86M | 4.08M | 2.38M | 1.29M | 721.18K | 347.75K | 513.06K | 185.99K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 2.75M | 4.05M | 3.62M | 3.52M | 1.05M | 1.02M | 161.77K | 55.57K | -836 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -133.38K | 0 | 0 | 0 | 0 | -60.83K | -54.95K | 0 | 0 |
| Operating Income | -11.18M | -11.92M | -7.7M | -5.89M | -2.34M | -1.74M | -509.52K | -586.63K | -203.89K |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -54.84% | -30.61% | -151.4% | -34.47% | -242.08% | 13.14% | -187.72% | - |
| EBITDA | -10.26M | -11.63M | -7.69M | -5.89M | -2.34M | -1.68M | -454.57K | -568.63K | -185.15K |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -10.81% | -51.18% | -30.67% | -151.75% | -38.98% | -270.05% | 20.06% | -207.12% | - |
| D&A (Non-Cash Add-back) | 923.43K | 290.11K | 5.46K | 6.81K | 5.97K | 60.83K | 54.95K | 18K | 18.74K |
| EBIT | -10.75M | -11.65M | -7.78M | -4M | -4.33M | -1.1M | -766.1K | -595.22K | -202.71K |
| Net Interest Income | -69.72K | -69.74K | -1.32M | -2.52M | -670.61K | -50.79K | -39.63K | 0 | 0 |
| Interest Income | 1.3K | 1.09K | 38.14K | 79.12K | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 71.02K | 70.83K | 1.36M | 2.6M | 670.61K | 50.79K | 39.63K | 30.92K | 10.88K |
| Other Income/Expense | 361.27K | 195.16K | -1.45M | -700.34K | -2.65M | 590.86K | -296.21K | -39.51K | -9.7K |
| Pretax Income | -10.82M | -11.72M | -9.14M | -6.59M | -5M | -1.15M | -805.73K | -626.14K | -213.59K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -10.82M | -11.72M | -9.14M | -6.59M | -5M | -1.15M | -805.73K | -626.14K | -213.59K |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -3.39% | -28.18% | -38.71% | -31.96% | -333.64% | -42.99% | -28.68% | -193.14% | - |
| Net Income (Continuing) | -10.82M | -11.72M | -9.14M | -6.59M | -5M | -1.15M | -805.73K | -626.14K | -213.59K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -21.51 | -71.60 | -8857.30 | -4.10 | -3.00 | -0.95 | -0.68 | -0.46 | -0.16 |
| EPS Growth % | -224.06% | 99.19% | -215931.71% | -36.67% | -217.46% | -38.16% | -48.37% | -193.63% | - |
| EPS (Basic) | - | -71.60 | -8857.30 | -4.10 | -3.00 | -0.95 | -0.68 | -0.46 | -0.16 |
| Diluted Shares Outstanding | 503.16K | 163.79K | 1.03M | 1.59M | 1.04M | 1.36M | 1.36M | 1.36M | 1.36M |
| Basic Shares Outstanding | 503.16K | 163.79K | 1.03M | 1.59M | 1.04M | 1.36M | 1.36M | 1.36M | 1.36M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Imminent liquidity insolvency risk
As indicated by the company's historical income statements, SHPH maintains a high-burn cost structure characterized by volatile R&D and SG&A outlays, with quarterly R&D expenses peaking at $1.6M in 2025Q1, reflecting the significant capital requirements necessary to sustain its ongoing clinical trial pipeline.
The firm's cost structure is dominated by non-discretionary clinical trial execution and administrative overhead, which consistently outpace any potential for near-term revenue generation. Investors should monitor the efficiency of these expenditures, as the lack of commercialized products renders the current expense profile entirely dependent on external financing to prevent operational cessation.
Based on reported financial data, SHPH exhibits a persistent negative operating margin, with quarterly operating losses fluctuating between $1.3M and $3.9M, demonstrating that the company lacks the scale to achieve operating leverage while remaining in a pre-revenue, clinical-stage development phase.
The absence of revenue means that every dollar spent on R&D and SG&A directly expands the operating deficit, leaving no room for operational efficiency gains. This trend suggests that the company's financial health is tethered to the successful completion of clinical milestones rather than internal cost-cutting measures.
According to recent income statement disclosures, SHPH utilizes stock-based compensation as a recurring expense, with a notable peak of $537.0K in 2025Q1, which further exacerbates the net losses reported by the firm during periods of intense clinical development activity.
The reliance on equity-based incentives in a cash-constrained environment suggests a strategy to preserve limited liquidity, though this comes at the cost of significant shareholder dilution. Analysts should interpret these figures as a signal of the company's ongoing struggle to balance talent retention with the preservation of its dwindling cash reserves.
As reported in financial filings, the company's cash position of $334,005 appears critically low relative to its historical quarterly burn rates, suggesting that the firm faces an immediate risk of insolvency without a rapid and potentially highly dilutive capital infusion.
Short-term observers may focus on the potential for the company's radiation-sensitization platform to disrupt oncology standards, yet the financial reality suggests that the runway is insufficient to reach meaningful clinical data readouts. The lack of revenue and the reliance on equity markets for survival warrant extreme caution regarding the firm's long-term viability.
Quick answers to the most common questions about buying SHPH stock.
For fiscal year 2025, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported total revenue of $0.0M.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported a net loss of $11.7M for the fiscal year ending 2025.